S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Relmada Therapeutics Earnings Date, Estimates & Call Transcripts (2022)

-0.69 (-3.63%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
281,933 shs
Average Volume
278,689 shs
Market Capitalization
$548.84 million
P/E Ratio
Dividend Yield
Price Target

Earnings Summary

Earnings Date
Aug. 9Estimated
Actual EPS
(May. 5)
-$1.40 Missed By -$0.19
Consensus EPS
(May. 5)
Last Year's Q2 EPS
Skip Charts & View Estimated and Actual Earnings Data

RLMD Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RLMD Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Relmada Therapeutics Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20222($1.26)($1.24)($1.25)
Q2 20223($1.30)($1.28)($1.29)
Q3 20223($1.36)($1.31)($1.33)
Q4 20223($1.40)($1.35)($1.38)
FY 202211($5.32)($5.18)($5.24)
Q1 20231($1.45)($1.45)($1.45)
Q2 20231($1.41)($1.41)($1.41)
Q3 20231($1.32)($1.32)($1.32)
Q4 20231($1.49)($1.49)($1.49)
FY 20234($5.67)($5.67)($5.67)

RLMD Earnings Date and Information

Relmada Therapeutics last announced its earnings results on May 5th, 2022. The reported ($1.40) earnings per share for the quarter, missing the consensus estimate of ($1.21) by $0.19. Relmada Therapeutics has generated ($7.20) earnings per share over the last year (($7.20) diluted earnings per share). Earnings for Relmada Therapeutics are expected to grow in the coming year, from ($5.41) to ($3.82) per share. Relmada Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 9th, 2022 based off prior year's report dates.

Relmada Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/5/2022Q1 2022($1.21)($1.40)($0.19)($1.40)
3/23/2022Q4 2021($1.60)($1.80)($0.20)($1.80)    
11/12/2020Q3 2020($1.05)($1.05)($1.05)
8/12/2020Q2 2020($0.55)($0.73)($0.18)($0.73)
8/12/2020Q2 2020($0.55)($0.73)($0.18)($0.73)
8/12/2020Q2 2020($0.55)($0.73)($0.18)($0.73)
5/15/2020Q1 2020($0.33)($0.72)($0.39)($0.72)
5/15/2020Q1 2020($0.33)($0.72)($0.39)($0.72)
5/15/2020Q1 2020($0.33)($0.72)($0.39)($0.72)
11/13/2019Q3 2019($0.38)($0.38)($0.38)
11/13/2019Q1 2020($0.38)($0.38)($0.38)
11/13/2019Q1 2020($0.38)($0.38)($0.38)
9/24/2019Q2 2019($0.44)($0.44)($0.44)
9/24/2019Q4 2019($0.44)($0.44)($0.44)
9/24/2019Q4 2019($0.44)($0.44)($0.44)
5/14/2019Q1 2019($0.36)($0.36)($0.36)
5/14/2019Q3 2019($0.36)($0.36)($0.36)
5/14/2019Q3 2019($0.09)($0.09)($0.09)
2/13/2019Q4 2018($1.12)($1.12)($1.12)
2/13/2019Q2 2019($1.12)($1.12)($1.12)
2/13/2019Q2 2019($0.28)($0.28)($0.28)
11/13/2018Q3 2018($1.08)($1.08)($1.08)
11/13/2018Q1 2019($1.08)($1.08)($1.08)
11/13/2018Q1 2019($0.27)($0.27)($0.27)
5/14/2018Q1 2018($1.04)($1.04)($1.04)
5/14/2018Q3 2018($1.04)($1.04)($1.04)
5/14/2018Q3 2018($0.26)($0.26)($0.26)
2/12/2018Q4 2017($0.44)($0.44)($0.44)
2/12/2018Q2 2018($0.44)($0.44)($0.44)
2/12/2018Q2 2018($0.11)($0.11)($0.11)
11/14/2017Q3 2017($0.32)($0.32)($0.32)
11/14/2017Q1 2018($0.32)($0.32)($0.32)
11/14/2017Q1 2018($0.08)($0.08)($0.08)
9/28/2017Q2 2017($0.52)($0.52)($0.52)
9/28/2017Q4 2017($0.52)($0.52)($0.52)
9/28/2017Q4 2017($0.13)($0.13)($0.13)
5/15/2017Q1 2017($0.64)($0.64)($0.64)
5/15/2017Q3 2017($0.64)($0.64)($0.64)
5/15/2017Q3 2017($0.16)($0.16)($0.16)
2/10/2017Q4 2016($0.36)($0.36)($0.36)
2/10/2017Q2 2017($0.36)($0.36)($0.36)
2/10/2017Q2 2017($0.09)($0.09)($0.09)
11/10/2016Q3 2016($0.56)($0.56)($0.56)
11/10/2016Q1 2017($0.56)($0.56)($0.56)
11/10/2016Q1 2017($0.14)($0.14)($0.14)
9/9/2016Q2 2016($0.72)($1.16)($0.44)($1.16)
9/9/2016Q4 2016($0.72)($1.16)($0.44)($1.16)
9/9/2016Q4 2016($0.18)($0.29)($0.11)($0.29)
5/9/2016Q1 2016($1.56)($0.60)+$0.96($0.60)
5/9/2016Q3 2016($1.56)($0.60)+$0.96($0.60)
5/9/2016Q3 2016($0.39)($0.15)+$0.24($0.15)
2/5/2016Q4 2015($1.68)($0.88)+$0.80($0.88)
2/5/2016Q2 2016($1.68)($0.88)+$0.80($0.88)
2/5/2016Q2 2016($0.42)($0.22)+$0.20($0.22)
11/6/2015Q3 2015$1.44+$1.44$1.44
11/6/2015Q1 2016$1.44+$1.44$1.44
11/6/2015Q1 2016$0.36+$0.36$0.36
5/15/2015Q2 2015($0.20)($0.20)($0.20)
5/15/2015Q4 2015($0.20)($0.20)($0.20)
5/15/2015Q4 2015($0.05)($0.05)($0.05)

Relmada Therapeutics Earnings - Frequently Asked Questions

When is Relmada Therapeutics's earnings date?

Relmada Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 9th, 2022 based off last year's report dates. Learn more on RLMD's earnings history.

Did Relmada Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Relmada Therapeutics (NASDAQ:RLMD) missed the analysts' consensus estimate of ($1.21) by $0.19 with a reported earnings per share (EPS) of ($1.40). Learn more on analysts' earnings estimate vs. RLMD's actual earnings.

How much profit does Relmada Therapeutics generate each year?

Relmada Therapeutics (NASDAQ:RLMD) has a recorded net income of -$125.75 million. RLMD has generated -$7.20 earnings per share over the last four quarters.

What is Relmada Therapeutics's EPS forecast for next year?

Relmada Therapeutics's earnings are expected to grow from ($5.41) per share to ($3.82) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:RLMD) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.